News | Proton Therapy | September 26, 2016

IBA and Philips Expanding Collaboration in Adaptive Proton Therapy Planning

Agreement includes joint marketing of proton therapy-related technologies, development of new technologies and new installations across the globe

IBA, Philips, adaptive proton therapy planning, ASTRO 2016, collaboration

September 26, 2016 — IBA (Ion Beam Applications S.A.) and Philips announced that they are stepping up their combined efforts in adaptive proton therapy planning through a new long-term collaboration agreement.

The collaboration between the two companies includes the joint marketing and sales of Philips’ imaging and clinical informatics solutions in oncology and IBA’s proton therapy solutions, and the joint development of new products for image-guided proton therapy and treatment modalities. IBA and Philips share the understanding that adaptive therapy planning is key to meeting this objective. The strategic partners have already secured certified compatibility between Philips’ Pinnacle3 therapy planning software and IBA’s proton therapy solution, and they will now jointly develop next-generation proton therapy planning methods to further increase efficiencies in the patient treatment workflow.

Also a result of the collaboration, more than 30 IBA proton therapy centers are expected to benefit from an enhanced cone beam computed tomography (CBCT) imaging technology. This advanced imaging technology provides the large field-of-view needed for enhanced image guidance during proton therapy procedures. To this end, a new software algorithm with an optimized balance between speed and image quality has been developed by the two long-term partners.

IBA and Philips are currently installing state-of-the-art proton therapy solutions at three compact proton therapy centers in the United Kingdom, one compact center in the Middle East, and one large proton therapy center in India. Depending on the proton therapy center, the installed solution can include IBA’s proton therapy systems, such as the Proteus One and Proteus Plus, and Philips’ imaging and clinical informatics solutions, such as Philips’ Big Bore CT and positron emission tomography (PET)/CT systems and Philips’ Pinnacle3 Treatment Planning System.

For more information: www.iba-worldwide.com, www.usa.philips.com/healthcare

Related Content

Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
Elekta Unity MR Linac system
News | Radiation Oncology | January 30, 2020
January 30, 2020 — Elekta announced that it signed a contract wit
IBA ProteusOne proton therapy system
News | Proton Therapy | January 29, 2020
January 29, 2020 — IBA (Ion Beam Applications S.A.) announced that it has signed a contract and received a major down